skip to main content

Cancer Surveillance Duration DM — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardMyositisCancer Surveillance Duration DMSCE Rheumatology

A 68-year-old with polymyalgia rheumatica relapses repeatedly during glucocorticoid taper despite diagnostic reassessment and adherence. Sarilumab is chosen. Which regimen matches its current UK PMR authorisation?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Give 200 mg subcutaneously every 2 weeks with a tapering corticosteroid course

Explanation lettering: C = shown as B · E = shown as C · B = shown as E

E is correct. For PMR with inadequate glucocorticoid response or relapse during taper, sarilumab is 200 mg subcutaneously every two weeks alongside a tapering corticosteroid course; it can continue as monotherapy after the taper. Evidence extends to one year, so treatment beyond 52 weeks is individualised according to disease activity, clinician judgement and patient choice.

Reference: Kevzara 200 mg pre-filled pen SmPC: https://www.medicines.org.uk/emc/product/15436/smpc